^
Association details:
| Biomarker: | MET overexpression + KDR overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
Published date:
03/16/2021
Excerpt:
Concomitant c-Met/VEGFR2 overexpression was associated with worse overall survival (13 months) compared with concomitant c-Met/VEGFR2 negative expression (19 months; p = 0.025)
DOI:
10.1038/s41598-021-85385-1
